Evidence map›Paper›PMID 37844081›Full record

ArticlePLoS neglected tropical diseases2023

Identifying key factors contributing to treatment costs for snakebite envenoming in private tertiary healthcare settings in Tamil Nadu, India.

Anika Salim, Jarred Williams, Samir Abdel Wahab, Tade Adeshokan, José R Almeida, Harry F Williams, Rajendran Vaiyapuri, Subramanian Senthilkumaran, Ponniah Thirumalaikolundusubramanian, Ketan Patel and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Cost of Snakebite and Its Impact on Household Economy in Southern Nepal.The American journal of tropical medicine and hygiene · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Anika SalimSchool of Pharmacy, University of Reading, Reading, United Kingdom.
Jarred WilliamsSchool of Pharmacy, University of Reading, Reading, United Kingdom.
Samir Abdel WahabSchool of Pharmacy, University of Reading, Reading, United Kingdom.
Tade AdeshokanSchool of Pharmacy, University of Reading, Reading, United Kingdom.
José R AlmeidaSchool of Pharmacy, University of Reading, Reading, United Kingdom.ORCID 0000-0002-4637-4468
Harry F WilliamsToxiven Biotech Private Limited, Coimbatore, Tamil Nadu, India.
Rajendran VaiyapuriToxiven Biotech Private Limited, Coimbatore, Tamil Nadu, India.
Subramanian SenthilkumaranManian Medical Centre, Erode, Tamil Nadu, India.
Ponniah ThirumalaikolundusubramanianThe Tamil Nadu Dr M.G.R Medical University, Chennai, Tamil Nadu, India.
Ketan PatelSchool of Biological Sciences, University of Reading, Reading, United Kingdom.
M Fazil BakshDepartment of Mathematics and Statistics, University of Reading, Reading, United Kingdom.
Matthew R LewinCalifornia Academy of Sciences, San Francisco, California, United States of America.
Sakthivel VaiyapuriSchool of Pharmacy, University of Reading, Reading, United Kingdom.ORCID 0000-0002-6006-6517
University of Reading · GBCalifornia Academy of Sciences · USPeriyar Maniammai Institute of Science & Technology · INTamil Nadu Dr. M.G.R. Medical University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndia suffers ~58,000 annual deaths due to snakebites. The 'Big Four' snakes (Russell's viper, Indian cobra, common krait, and saw-scaled viper) that are responsible for most bites cause diverse clinical effects. Delayed treatment increases the risk of serious complications and treatment costs. Although government hospitals offer free treatment for snakebites in India, most patients opt for private healthcare, which is an out-of-pocket expense as they often lack health insurance coverage. This study aims to analyse snakebite treatment costs in private tertiary care hospitals in Tamil Nadu, India and identifies the key factors contributing to treatment costs. METHODOLOGY/PRINCIPAL

findingsThe treatment cost details for 913 snakebite victims were collected from 10 private tertiary care hospitals across Tamil Nadu. The data were classified into hospital, pharmacy, investigation, and laboratory costs, and analysed to determine various factors that contribute to the costs. The results demonstrate that the average treatment costs vary widely for different snakes. The hospital and pharmacy costs are higher than investigation and laboratory costs for all snakebites. Notably, Russell's viper bites cost significantly more than the bites from other snakes. Overall, the type of snake, nature of complications, specialist treatments required, and arrival time to hospitals were identified as some of the key factors for higher treatment costs. CONCLUSIONS/SIGNIFICANCE: These data demonstrate that ~80% of snakebite patients can be treated with INR 100,000 (~GBP 1000 or USD 1200) or less. This study emphasises the urgent need to improve rural medical care by providing appropriate training for healthcare professionals and essential resources to facilitate early assessment of patients, administer the initial dose of antivenom and refer the patients to tertiary care only when needed. Moreover, the outcome of this study forms a basis for developing appropriate policies to regulate snakebite treatment costs and provide affordable medical insurance for vulnerable communities.

Indexed as

DaboiaSnake BitesViperidaeAnimalsAntiveninsHealth Care CostsHumansIndiaTertiary Health CareAntivenins

Identifiers

PMID37844081
PMCPMC10602377
OpenAlexW4387665968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.